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The prognosis of renal cell carcinoma with brain metastasis is generally poor. Here we report a case of a
56-year-old man with metastatic renal cell carcinoma to the brain who underwent metastasectomy,
cytoreductive nephrectomy, and whole brain radiotherapy. Thereafter, he received sunitinib, everolimus,
and sorafenib sequentially for 11 months, 2 months, and 2 months, respectively. No tumor recurrence or
progression of brain lesions has been reported in this patient for the past 16 months.
Copyright  2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Approximately 10% of patients with renal cell carcinoma
develop brain metastasis within 5 years.1 Because of the lack of an
effective treatment for this chemo- and radio-resistant malignancy,
the prognosis of these patients is often poor. Brain involvement
implies possible neurological sequelae and may decrease the
quality of life of the patients. The median survival time after the
diagnosis of brain metastases in patients with metastatic renal cell
carcinoma (mRCC) is only approximately 10 months, although
stereotactic radiosurgery has been widely used in recent decades.2
In the past 5 years, several targeted agents such as tyrosine
kinase inhibitors and mammalian target of rapamycin inhibitors
have been approved for the treatment of patients with mRCC.
However, patients with brain metastases are usually excluded from
enrolment in these clinical trials. Extended access programs for
sunitinib and sorafenib have supported the safe use of these drugs
in such patients.3,4 Furthermore, in a few case reports, sunitinib and
sorafenib resulted in a positive response with regard to treatment
of brain mRCC.5,6 Herewe report a case of a patient withmRCCwhortment of Surgery, Taichung
ang Road, Taichung, Taiwan,
).
ciation. Published by Elsevier Taiwshowed prolonged disease control of brain metastases following
surgery, radiotherapy, and use of targeted agents.2. Case report
In May 2010, a 56-year-old man presented to our hospital with
the chief complaint of progressive left lower limb weakness for the
past 3 weeks. Magnetic resonance imaging (MRI) of the brain
revealed a 33-mm enhanced mass with perifocal edema over the
right frontal area (Fig. 1A). The patient underwent right frontal
craniotomy for removal of the tumor. Pathology showed a poorly
differentiated metastatic carcinomawith immunoreactivity to AE1/
AE3 but not to CK7, CK20, or TTF-1. Chest and abdominal computed
tomography (CT) showed a 9-cm left renal tumor with multiple
metastases to the pelvic bone, lung, retroperitoneum, and medi-
astinal lymph nodes. Left radical nephrectomy with lymph node
dissection was performed and pathology showed a clear cell-type
renal cell carcinoma stage T3N1M1. Brain CT prior to sunitinib
treatment in June 2010 showed a tiny residual tumor above the
right frontal lobe (Fig. 1B). The patient then underwent whole brain
radiotherapy at a dosage of 3000 cGy.
The patient received sunitinib 50 mg daily with a 4/2 schedule 4
weeks after craniotomy. Adverse effects of the drug included Grade
2 fatigue, Grade 2 handefoot syndrome, and Grade 1 nausea, which
were all tolerable; thus, dosage adjustment was not necessary.an LLC. Open access under CC BY-NC-ND license.
Fig. 1. Brain imaging of the patient with mRCC to the brain. (A) Initial magnetic resonance imaging showed a 33-mm mass above the right frontal lobe. (B) A residual 8-mm tumor
was detected on computed tomography (CT) after removal of the brain tumor. (C) The patient received radiotherapy and sunitinib for 11 months; CT during follow-up showed
complete response. (D) No recurrence was observed on CT after switching the patient to everolimus for 3 months and sorafenib for 2 months sequentially.
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lesion (Fig. 1C). The best response of extracranial metastases was
stable disease with mild regressive change on follow-up. In July
2011, progression of the pelvic bone metastases was detected, and
we shifted the treatment to targeted therapy using everolimus
10 mg daily as continuous dosing for second-line therapy. In
September 2011, progression of the lung and pelvic bone metas-
tases was observed, coupled with the recurrence of retroperitoneal
lymph node metastases. Grade 2 adverse effects such as elevated
serum creatinine levels, hypertension, hyperglycemia, and hyper-
cholesterolemia were observed. We discontinued everolimus for 2
weeks and switched the patient to sorafenib 400 mg twice daily
with continuous dosing. Grade 2 handefoot syndrome was re-
ported. The last brain CT in October 2011, 16 months after the
diagnosis of brain metastases, showed no tumor recurrence
(Fig. 1D). The switch from sunitinib to second-line targeted agents
did not result in central nervous system (CNS) recurrence for at
least 4 months.
3. Discussion
The latest European Association of Urology (EAU) guidelines for
renal cell carcinoma have suggested the use of cytoreductive ne-
phrectomy and metastasectomy in patients with mRCC.7 Radio-
therapy can be used for patients with nonresectable brain
metastatic lesions; however, renal cell carcinoma is relatively
radio-resistant. Unfortunately, the combination of these modalities
has not been extensively discussed in the literature. According to
the results of a retrospective study, surgical resection and/or ste-
reotactic radiosurgery for brain metastases should be considered in
single or limited lesions, because these improve the overall survival
of patients compared with whole brain radiotherapy alone.8 We
also used all these modalities in the current patient, although it
would have been better if we had identiﬁed the primary lesion of
brain metastasis prior to metastasectomy.
The early development of new brain lesions or local recurrence
after CNS treatment remains a challenge. Systemic treatments, such
as immunotherapy, chemotherapy, and targeted therapy have been
considered for better control. In a retrospective study, tyrosine ki-
nase inhibitors signiﬁcantly reduced the incidence of brain me-
tastases and the development of new brain lesions.9 However, for
patients with residual or naïve multiple brain metastases, evidence
of their efﬁcacy is limited,5,6 because these patients are usually
excluded from clinical trials involving targeted agents.
The bloodebrain barrier limits the passage of macromolecules
into the brain tissue. Thus, chemotherapeutic agents have long
been considered to have limited efﬁcacy in the treatment of brainmetastases. However, observational studies have revealed the ef-
ﬁcacy of targeted therapy in the treatment of brainmetastases from
lung, breast, or renal cancer,10 possibly through the disruption of
the barrier during brain metastases. In the extended access pro-
grams for sunitinib and sorafenib, the incidence of treatment-
related adverse effects in the brain metastatic group was similar
to that in the general mRCC population.3,4 The adverse event of
most concern, cerebral hemorrhage, occurred in a single person out
of a total of 283 cases. In our patient, the residual tumor dis-
appeared and no recurrence was detected for 16 months after
whole brain radiotherapy and sequential use of targeted agents. As
mentioned earlier, whole brain radiotherapy has limited effects on
renal cell carcinoma, thus sunitinib may have played the most
important role in achieving a complete response. The sequential
use of everolimus and sorafenib may also have had the same effect
as sunitinib in maintaining at least 4 months of CNS disease-free
survival in this patient. During this period, sunitinib, everolimus,
and sorafenib were used sequentially for 11 months, 2 months, and
2 months, respectively, and no intracranial hemorrhage was
observed. Although metastases of the bone and retroperitoneum
progressed, the observed CNS disease-free survival was better than
that reported previously, which were 13 months with a single
metastatic lesion and 4 months with multiple lesions.2 The overall
survival time was also much longer than the mean overall survival
time reported in the same study (16 months vs. 10.4 months). The
sequential use of targeted agents was well tolerated and effective in
our patient. However, the potential application of our ﬁndings is
limited by the size of our study. Further studies with a large patient
cohort using targeted therapy in the treatment of brain metastasis
are warranted.
In this case, aggressive intervention using surgery, radiotherapy,
and sequential use of targeted agents achieved long-term survival.
Targeted agents may play an important role in the treatment of
brain metastases from renal cell carcinoma. The sequential use of
targeted agents should be considered to prolong the control of
mRCC, including those involving brain metastases.Conﬂicts of interest
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